272 reports of this reaction
3.2% of all REGADENOSON reports
#8 most reported adverse reaction
DIZZINESS is the #8 most commonly reported adverse reaction for REGADENOSON, manufactured by Astellas Pharma US, Inc.. There are 272 FDA adverse event reports linking REGADENOSON to DIZZINESS. This represents approximately 3.2% of all 8,610 adverse event reports for this drug.
Patients taking REGADENOSON who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among REGADENOSON users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for REGADENOSON:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 272 FDA reports for REGADENOSON. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 3.2% of all adverse event reports for REGADENOSON, making it a notable side effect.
If you experience dizziness while taking REGADENOSON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.